Stryker Co. (NYSE:SYK) Shares Purchased by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC lifted its stake in shares of Stryker Co. (NYSE:SYK) by 3.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,950 shares of the medical technology company’s stock after acquiring an additional 183 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Stryker were worth $1,482,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of SYK. Vanguard Group Inc. raised its position in shares of Stryker by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock worth $8,379,967,000 after acquiring an additional 143,631 shares in the last quarter. FMR LLC lifted its position in shares of Stryker by 2.5% during the 3rd quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after buying an additional 144,208 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Stryker by 4.4% in the 3rd quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock valued at $1,452,493,000 after buying an additional 223,728 shares in the last quarter. Fisher Asset Management LLC raised its stake in Stryker by 2.6% during the 4th quarter. Fisher Asset Management LLC now owns 4,042,317 shares of the medical technology company’s stock worth $1,210,512,000 after acquiring an additional 103,326 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Stryker by 3.9% in the third quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock valued at $957,974,000 after acquiring an additional 131,590 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on SYK shares. Robert W. Baird lifted their target price on Stryker from $367.00 to $378.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Wednesday, May 1st. Evercore ISI upped their price target on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Stifel Nicolaus raised their price objective on shares of Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, BTIG Research upped their target price on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $365.94.

Insider Buying and Selling at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Stryker Trading Up 0.6 %

NYSE SYK opened at $328.45 on Monday. The firm’s fifty day simple moving average is $346.99 and its 200-day simple moving average is $317.97. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The company has a market capitalization of $125.12 billion, a PE ratio of 37.49, a price-to-earnings-growth ratio of 2.56 and a beta of 0.91.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.14 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 11.94 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were issued a $0.80 dividend. The ex-dividend date was Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.97%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.